Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study.

@article{Ong2011OralLI,
  title={Oral L-ornithine-L-aspartate improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: an open-label, prospective, multicentre observational study.},
  author={Janus P. Ong and Gerd Oehler and Christiane Kr{\"u}ger-Jansen and Judith Lambert-Baumann and Zobair M Younossi},
  journal={Clinical drug investigation},
  year={2011},
  volume={31 4},
  pages={213-20}
}
BACKGROUND AND OBJECTIVE Hepatic encephalopathy (HE) is a serious complication of cirrhosis. Clinical trials have consistently shown that L-ornithine-L-aspartate significantly improves HE symptoms. Health-related quality of life (HR-QOL) is impaired in HE patients and represents an important outcome measure for therapeutic intervention. The present study aimed to assess the impact of L-ornithine-L-aspartate on HR-QOL and safety in patients with HE in a clinical practice setting. METHODS This… CONTINUE READING

Similar Papers

Loading similar papers…